Results 171 to 180 of about 1,794,315 (321)

The Influence of Surgeons' Gender on Surgical Outcomes in Laparoscopic Right Hemicolectomy: A Japanese Nationwide Retrospective Cohort Study

Annals of Gastroenterological Surgery, EarlyView.
This study analyzed 58 503 laparoscopic right hemicolectomies for colon cancer in Japan between 2018 and 2022, comparing outcomes between male and female surgeons. No significant differences were found in surgical mortality or severe complications. Tailored surgical training programs for female surgeons may further enhance surgical outcomes.
Akihisa Matsuda, Hideki Endo, Aya Yamagishi, Hiroyuki Yamamoto, Shuji Takiguchi, Koki Otsuka, Takeshi Yamada, Hiroshi Yoshida, Hideki Ueno, Yuko Kitagawa, Ken Shirabe   +10 more
wiley   +1 more source

Real‐time fault detection in multicomponent nuclear‐waste slurries through data fusion of spectroscopic sensors

AIChE Journal, EarlyView.
Abstract Three instruments–Raman spectroscopy, attenuated total reflectance–Fourier transform infrared spectroscopy, and focused beam reflectance measurement–were used to detect sensor faults, mixing faults, and unanticipated chemistry in a system of multicomponent slurries.
Steven H. Crouse, Ronald W. Rousseau, Martha A. Grover   +2 more
wiley   +1 more source

[Retracted] Extreme Anemia (Hemoglobin 1.8 g/dL) Secondary to Abnormal Uterine Bleeding [PDF]

, 2017
Ketaki Panse, R. Regn, Jonathan May
openalex   +1 more source

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study

American Journal of Hematology, EarlyView.
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Rami S. Komrokji, Sheida Hayati, Manuel Ugidos, Guillermo Garcia‐Manero, Matteo Giovanni Della Porta, Amer M. Zeidan, Valeria Santini, Uwe Platzbecker, Anita K. Gandhi, Rajasekhar N. V. S. Suragani   +9 more
wiley   +1 more source

Hemoglobinas anormais em sangue de cordão umbilical Abnormal hemoglobins in umbilical cord blood

Revista Brasileira de Hematologia e Hemoterapia, 2006
Lízia Maria F. R. Campos, Francisca L. Dias, Marcel Mendes   +2 more
doaj   +1 more source

Síndromes talamésicos. Nuevos conceptos y estado actual del conocimiento en Costa Rica

Acta Médica Costarricense, 2006
En tanto que para las hemoglobinas Hbs anormales es posible determinar los lugares de su origen (marcadores antropológicos), en las enfermedades talasémicas se tiene el problema de su amplia distribución en las principales poblaciones ancestrales.
German F Sáenz-Renauld, Walter Rodríguez-Romero   +1 more
doaj  

Visual detection of abnormal hemoglobin with a procedure for glycated hemoglobin. [PDF]

, 1984
Cooper Howard, Nancy Reddig, Keith M. Meek   +2 more
openalex   +1 more source

Studies on abnormal hemoglobins. XIII. Hemoglobin S-thalassemia disease and hemoglobin C-thalassemia disease in siblings.

Blood, 1957
Karl Singer, Aaron M. Josephson, L. Singer, Paul Heller, Hyman J. Zimmerman   +4 more
semanticscholar   +1 more source

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

American Journal of Hematology, EarlyView.
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs, Elizabeth A. Abels, Brian D. Adkins, Garrett S. Booth, Victoria Costa, Sheharyar Raza, Michelle Simon, Jennifer S. Woo, Allison P. Wheeler   +8 more
wiley   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

American Journal of Hematology, EarlyView.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang, Ruonan Li, Qian Liang, Weiwang Li, Hong Pan, Zhen Gao, Liwei Fang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Jun Li, Hong Zhang, Jun Shi   +18 more
wiley   +1 more source